Ken Griffin Galecto, Inc. Put Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$0.47 - $0.76 $47 - $76	-100 Reduced 50.0%	100 $0
Q1 2024 May 15, 2024	BUY	$0.6 - $0.89 $120 - $178	200 New	200 $0
Q2 2023 Aug 14, 2023	BUY	$1.68 - $2.84 $3,024 - $5,112	1,800 Added 180.0%	2,800 $7,000
Q1 2023 May 15, 2023	BUY	$1.21 - $2.86 $1,210 - $2,860	1,000 New	1,000 $1,000

1.52M

100

100

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $186M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.